Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT02780167. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER, DOSE-RANGING, STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize the efficacy and safety of PF 04965842 in subjects with moderate to severe AD. The objectives of the study are to demonstrate the efficacy of PF 04965842 by showing improvement in disease severity in patients with moderate to severe AD as measured by the Investigator's Global Assessment (IGA) and Eczema Area and Severity Index (EASI) scores, and safety to support further clinical development of PF 04965842.
Study identification
- NCT ID
- NCT02780167
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 269 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2016 (Actual)
- Primary completion
- Mar 2017 (Actual)
- Completion
- Apr 2017 (Actual)
- Last update posted
- May 2, 2019
2016 – 2017
United States locations
- U.S. sites
- 37
- U.S. states
- 20
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Center of Alabama | Birmingham | Alabama | 35209 | — |
| California Dermatology & Clinical Research Institute | Encinitas | California | 92024 | — |
| Huntington Medical Foundation | Pasadena | California | 91105 | — |
| Peninsula Research Associates, Inc. | Rolling Hills Estates | California | 90274 | — |
| Emil A. Tanghetti MD dba Center for Dermatology and Laser Surgery | Sacramento | California | 95819 | — |
| TCR Medical Corporation | San Diego | California | 92123 | — |
| Clinical Science Institute | Santa Monica | California | 90404 | — |
| University of Connecticut Health Center (UConn Health) | Farmington | Connecticut | 06032 | — |
| Olympian Clinical Research | Clearwater | Florida | 33756 | — |
| North Florida Dermatology Associates, PA | Jacksonville | Florida | 32204 | — |
| Park Avenue Dermatology Administration Annex | Orange Park | Florida | 32073 | — |
| Park Avenue Dermatology | Orange Park | Florida | 32073 | — |
| Leavitt Medical Associates of Florida d/b/a Ameriderm Research | Ormond Beach | Florida | 32174 | — |
| Forward Clinical Trials, Inc. | Tampa | Florida | 33624 | — |
| MedaPhase, Inc. | Newnan | Georgia | 30263 | — |
| Dundee Dermatology | West Dundee | Illinois | 60118 | — |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | 46256 | — |
| Dawes Fretzin Dermatology Group, LLC | Indianapolis | Indiana | 46256 | — |
| The Indiana Clinical Trials Center | Plainfield | Indiana | 46168 | — |
| DS Research | Louisville | Kentucky | 40241 | — |
| Shondra L Smith, MD Dermatology & Advanced Aesthetics | Lake Charles | Louisiana | 70605 | — |
| Somerset Skin Centre | Troy | Michigan | 48084 | — |
| MediSearch Clinical Trials | Saint Joseph | Missouri | 64506 | — |
| Clinical Research Consortium | Las Vegas | Nevada | 89119 | — |
| Psoriasis Treatment Center of Central New Jersey | East Windsor | New Jersey | 08520 | — |
| The Dermatology Group, P.C | Verona | New Jersey | 07044 | — |
| Forest Hills Dermatology Group | Forest Hills | New York | 11375 | — |
| Sadick Research Group | New York | New York | 10075 | — |
| Vital Prospects Clinical Research Institute, P.C | Tulsa | Oklahoma | 74136 | — |
| DermDox Centers for Dermatology | Hazleton | Pennsylvania | 18201 | — |
| UPMC Department of Dermatology | Pittsburgh | Pennsylvania | 15213 | — |
| Clinical Partners, LLC | Johnston | Rhode Island | 02919 | — |
| Health Concepts | Rapid City | South Dakota | 57702 | — |
| Bellaire Dermatology Associates | Bellaire | Texas | 77401 | — |
| Texas Dermatology and Laser Specialists | San Antonio | Texas | 78218 | — |
| Virginia Clinical Research,Inc | Norfolk | Virginia | 23502 | — |
| West End Dermatology Associates | Richmond | Virginia | 23233 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02780167, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 2, 2019 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02780167 live on ClinicalTrials.gov.